Skip to content

COVID-19 Superinfection with Aspergillus spp. (COSIA)

COVID-19 Superinfection with Aspergillus spp. (COSIA) - COSIA

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00024578
Enrollment
522
Registered
2021-03-09
Start date
2021-02-01
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

U07.1 B44.0

Interventions

Group 1: The cohort will be retrospectively collected and analyzed after admission to an intensive care unit. Patients with definite CAPA infection will be randomly matched to drawn controls without C

Sponsors

Charité Universitätsmedizin Berlin
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 120 Years

Inclusion criteria

Inclusion criteria: severe case of Covid-19

Exclusion criteria

Exclusion criteria: no stay on intensive care unit

Design outcomes

Primary

MeasureTime frame
The primary endpoint of the study is the risk factors for developing CAPA. The cohort will be retrospectively collected and analyzed after admission to an intensive care unit. Patients with definite CAPA infection will be randomly matched to controls without CAPA infection. Clinical and laboratory parameters will be collected and patients will be compared based on these parameters. It is an explorative nested-case-control study. The parameters will be collected from the hospital information system.

Secondary

MeasureTime frame
Dexametason as risk factor für CAPA.

Countries

Germany

Contacts

Public ContactRasmus Leistner

Charité Universitätsmedizin Berlin

rasmus.leistner@charite.de+49 30 450 570 043

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 19, 2026